Kenneth Barr holds a PhD in Synthetic Organic/Organometallic Chemistry from the Massachusetts Institute of Technology and completed his postdoctoral research in natural product synthesis at the University of Texas. He brings over three decades of experience in therapeutics discovery, with prior associations at Abbott Laboratories, Merck, Amplyx, and Sunesis. Before joining Syngene, Kenneth served as Head of R&D Strategic Global Operations at FORMA Therapeutics, where he was responsible for driving research effectiveness through optimization of internal and external R&D efforts, as well as alliance management for key.